

ation is coordinating efforts with the FDA to establish "equivalence" criteria for substitute materials in shortage areas and to keep critical devices on the market (1).

In the short run, the most effective remedy would be to change tort law to bar product liability claims against remote suppliers of "off the shelf" commodity materials and components of devices that have received FDA approval. The entire liability burden would then fall on the device manufacturer, who could decide whether or not to market a device.

Better solutions might be generated through discussion with all involved parties. However, a temporary resolution is urgently needed if we are to avoid a shortage of chronic implants for critically ill patients.

Pierre M. Galletti*

President, American Institute for
Medical and Biological Engineering,
Division of Biology and Medicine,
Brown University,
Providence, RI 02912, USA

References

1. J. A. Gould *et al.*, *J. Appl. Biomed.* 4, 355 (1993).

*Co-signers: **James M. Anderson**, Case-Western Reserve University; **Joseph D. Andrade**, University of Utah; **Robert E. Baier**, University of Buffalo; **Harvey S. Borovetz**, University of Pittsburgh; **Stuart Cooper**, University of Delaware; **William J. Dorson**, Arizona State University; **Robert C. Eberhart**, University of Texas, Arlington; **Allan S. Hoffman**, University of Washington; **Adrian Kantrowitz**, Sinai Hospital, Detroit; **Robert Langer**, Massachusetts Institute of Technology; **Edward Leonard**, Columbia University; **Robert Nerem**, Georgia Tech; **Yukihiko Nosé**, Baylor College of Medicine; **Don B. Olsen**, University of Utah; **Nicholas A. Peppas**, Purdue University; **William S. Pierce**, Pennsylvania State University; **Alfred R. Potvin**, Indiana University Purdue University, Indianapolis; **Buddy D. Ratner**, University of Washington; **Ioannis V. Yannas**, Massachusetts Institute of Technology; **Ajit P. Yoganathan**, Georgia Tech; **Andreas von Recum**, Clemson University.

Cholesterol Vaccines

John Travis's Research News article of 24 December (p. 1974) discusses vaccines to protect against atherosclerosis. Variations of this approach have been tested previously (1-6). Cholesterol-fed rabbits were protected against atherosclerosis by immunizing them with β -lipoproteins (1), and the response of rats to dietary cholesterol was reduced by stimulating the reticuloendothelial (RE) system using zymosan (2). In our work, cholesterol-fed rabbits were immunized with synthetic antigens in which cholesterol-esters were covalently linked, as haptens, to various protein carriers (3-7). Significant reductions in serum cholesterol and up to 90% protection against atherosclerotic plaques were obtained.

In a discussion of the work of the Army group (8), the question was raised whether the immune system will develop antibodies to a common constituent such as cholesterol. We found that significant titers were retained against cholesterol after absorption with carrier protein, and extensive cross-reaction was exhibited with cholesterol conjugates of unrelated carrier proteins. This confirmed that antibodies directed specifically against cholesterol could be induced by immunization.

The article also questions how immunization lowers blood cholesterol. We observed increases of greater than 70% in the clearance of ^{14}C -cholesterol-esters from serum of immunized animals (5). Significant amounts of cholesterol-antibody complexes were also detected in serum. These observations led to the proposal that the antibodies might label cholesterol-containing lipoproteins for clearance by scavenging macrophages (6).

Travis mentions possible long-term adverse effects of the vaccination procedure. In experiments lasting up to 9 months, the hypocholesterolemic effects of immunization persisted, but the protective effects against atherosclerosis gradually declined, despite monthly booster shots. No evidence of autoimmune phenomena or other side effects were noted (7).

The cholesterol-fed rabbit may be too severe a test for the cholesterol vaccination procedure. Serum cholesterol in this model frequently exceeds 2000 milligrams per deciliter (mg/dl), whereas the clearance capacity of the RE system is about 300 mg/dl (7). The bulk of the public health problem involves cholesterol in the range of 200 to 500 mg/dl. If the procedure can be validated in a more appropriate model, it could become a useful adjunct to diet or drug therapy. However, many technical obstacles would need to be overcome before the scenario of a routine "cholesterol vaccination" could become a reality.

J. Martyn Bailey

Department of Biochemistry,
and Molecular Biology,
George Washington University
School of Medicine,
Washington, DC 20037, USA

References


1. S. Gero *et al.*, *Lancet* i, 6 (1959); *ibid.* ii, 1119 (1961).
2. S. J. Riggi and N. R. DiLuzio, *J. Lipid Res.* 3, 339 (1962).
3. J. M. Bailey, R. Bright, R. Tomar, *Nature* 201, 407 (1963).
4. J. M. Bailey and R. Tomar, *J. Atheroscler. Res.* 5, 203 (1965).
5. J. M. Bailey, *Arch. Mat. Coeur Vaiss.* 60, 204 (1967).
6. — and J. Butler, in *The Reticuloendothelial System and Atherosclerosis*, N. R. DiLuzio, Ed. (Plenum, New York, 1967), pp. 433-441.

Opinion

A New View of Synthetic Polymers

The current methodology for the analysis of synthetic polymers, although well established, leaves a lot to be desired. Reliable results depend heavily on the availability of known and well characterised standards. A variety of techniques – for example GPC, light scattering, viscosity measurements and NMR may have to be used to characterise a single polymer.

Matrix assisted laser desorption/ionisation (MALDI) with the Vision 2000 may provide all the answers in a single simple experiment which will take less than 20 minutes to perform, including sample preparation.



The MALDI spectrum of a polymer distribution will not only allow you to calculate Mw, Mn and Mp from a single measurement, but it will also indicate the repeating unit as well as the end group of the polymer.

The Vision 2000 can deal with mixtures without separation and do all this without the need for standards. If your polymerisation took an unexpected course MALDI will tell you right away.

With the appropriate matrix MALDI can analyse almost any type of polymer, determining accurate molecular masses well beyond 200 000 Dalton. In the analysis of lower molecular weight oligomers – e.g. below 5 000 Dalton where GPC is of little use – the Vision 2000 reveals all structural details with its high mass resolving power.

It is time for you to take a new look at your polymer analysis.

**Finnigan
MAT**

Germany: (+49)421/5493-0, Fax 5493-396
U.K.: (+44)442/233555, Fax 233666
USA: (+1)408/433 4800, Fax 433 4823
Japan: (+81)03/3372 3001, Fax 3372 7051

The OPINION column features technical tips & preliminary information relating to instruments designed & built at Finnigan MAT GmbH, Bremen, Germany.

7. J. M. Bailey, R. Bright, R. Tomar, J. Butler, *Biochem. Soc. Trans.*, in press.
8. G. M. Swartz, M. K. Gentry, L. M. Amende, E. J. B-Macki, C. R. Alving, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 1902 (1988).

Fire and Ice . . . and Worms?

May I point out that the "Würmertod" referred to in the Vignette from Karl Sigmund's book *Games of Life: Explorations in Ecology, Evolution, and Behaviour* (Oxford Univ. Press, New York, 1993) in the issue of 29 April (Book Reviews, p. 727) means "death of the worms." This is not at all identical with the once-predicted *Wärmetod*, the hypothetical death of a universe coming into perfect thermal equilibrium. It is highly probable that the *Wärmetod* would be preceded by a *Würmertod*, although it must be noted that these hardy animals did manage to survive the *Wärm-Eiszeit*.

Lucien F. Trueb
Science and Technology Editor,
Neue Zürcher Zeitung,
8021 Zurich, Switzerland

Corrections and Clarifications

In the Perspective "α-Helical coiled coils: More facts and better predictions" by C. Cohen and D. A. D. Parry (28 Jan., p. 488), the second sentence of the second paragraph of column 1 on page 489 should have read, "The structural motif is indeed a left-handed three-helix bundle with left-handed chain connectivity."


Correction

29 April (p. 734)
and
13 May (p. 911)
issues of

Science

The talk being given by Dr. Harold Varmus at the *Science/HUGO* Human Genome 1994 meeting on Monday, 3 October, in Washington, D.C., is entitled "Manipulating Cancer Genes in the Mouse."

Yes, Sequence Comparisons



The most comprehensive sequence comparison capabilities ever assembled on a desktop are all just one part of IBI MacVector™ Sequence Analysis software. With MacVector you options include:

- DNA & protein sequence searches on the Entrez: Sequences CD including: GenBank, SWISS-PROT, EMBL, PIR and DDBJ.
- Multiple sequence alignments
- Homology matrixes
- User selectable gap/deletion penalties
- Scoring matrixes for all comparisons

And much more. All in an intuitive Mac format that you'll understand in minutes without even reading the manual. In fact, if you're not totally impressed after just 30 days, we'll buy it back, no questions asked. Order yours today. **1-800-243-2555**. Outside the U.S. (203) 786-5600.

MacVector™



Scientific Imaging Systems
EASTMAN KODAK COMPANY
25 Science Park, New Haven, CT 06511

Macintosh is a trademark of Apple Computers, Inc.
© 1994 EASTMAN KODAK COMPANY


Circle No. 31 on Readers' Service Card



Mo Bi Tec

Exontrap

A new DNA cloning vector for the selective cloning of exons



The Exontrap shuttle vector enables the cloning of genomic DNA in *E. coli*. The cloned vector is then transfected into eucaryotic cells where the DNA is transcribed into RNA. The RNA is processed into mRNA (the introns are eliminated). From the mRNA cDNA is synthesized using suitable primers. The cDNA is amplified and the fragments can be cloned directly.

Advantages:

- provides selective cloning of exons
- identifies unknown eucaryotic genes
- includes a complete system with all primers, descriptions and protocols

Mo Bi Tec

Wagenstieg 5, D-37077 Göttingen, FRG
Tel: +49 551 37 10 62 Fax: +49 551 34 987
USA: USB Tel: 800-321-9322; 216-765-5000
Japan: Funakoshi Tel: 03-5684-1620

Circle No. 9 on Readers' Service Card